ClinicalTrials.gg
Active, not recruitingNCT05987670TRICORDERUpdated Nov 10, 2026

Triple Cardiovascular Disease Detection With an Artificial Intelligence-enabled Stethoscope

An interventional study of AI-stethoscope in Heart Failure, Heart Valve Diseases and Atrial Fibrillation, sponsored by Imperial College London. Active, not recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Imperial College London · Not applicable, Interventional, and Diagnostic

How we know

Updated Nov 10, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Heart Failure by Imperial College London — 7 open to participants now, 8 under way, none of them phase 3. Heart Failure · Imperial College London.

Enrollment
3rd of 18
200 · median 55
Started
2023
with 4 others
No phase
11 of 29
5 open now
Registered
24th of 29
by date

Among the 29 studies in Heart Failure by Imperial College London, this one is the 3rd largest by enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2023, is one of 11 with no phase, and was the 24th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

7 of the 29 studies in Heart Failure by Imperial College London are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Heart Failure by Imperial College London, or all of them as a file.
02

Study summary

Heart failure (HF) is a condition in which the heart cannot pump blood adequately. It is increasingly common, consumes 4% of the UK National Health Service (NHS) budget and is deadlier than most cancers. Early diagnosis and treatment of HF improves quality of life and survival. Unacceptably, 80% of patients have their HF diagnosed only when very unwell, requiring an emergency hospital admission, with worse survival and higher treatment costs to the NHS. This is largely because General Practitioners (GPs) have no easy-to-use tools to check for suspected HF, with patients having to rely on a long and rarely completed diagnostic pathway involving blood tests and hospital assessment.

The investigators have previously demonstrated that an artificial intelligence-enabled stethoscope (AI-stethoscope) can detect HF in 15 seconds with 92% accuracy (regardless of age, gender or ethnicity) - even before patients develop symptoms. While the GP uses the stethoscope, it records the heart sounds and electrical activity, and uses inbuilt artificial intelligence to detect HF.

The goal of this clinical trial is to determine the clinical and cost-effectiveness of providing primary care teams with the AI-stethoscope for the detection of heart failure. The main questions it aims to answer are if provision of the AI-stethoscope:

  1. Increases overall detection of heart failure
  2. Reduces the proportion of patients being diagnosed with heart failure following an emergency hospital admission
  3. Reduces healthcare system costs

200 primary care practices across North West London and North Wales, UK, will be recruited to a cluster randomised controlled trial, meaning half of the primary care practices will be randomly assigned to have AI-stethoscopes for use in direct clinical care, and half will not. Researchers will compare clinical and cost outcomes between the groups.

Read the detailed description

Triple Cardiovascular Disease Detection with Artificial Intelligence-enabled Stethoscope (TRICORDER) is an open label, cluster randomised controlled trial. The aim is to determine whether use of an artificial intelligence-enabled stethoscope (AI-stethoscope) in UK Primary Care improves community-based detection of heart failure (HF), compared with usual care. 200 primary care practices in North West London (UK) will be randomised to receive the AI-stethoscope (intervention arm) or continue with usual care (control arm). The intervention arm will use the AI-stethoscope in routine clinical practice. Outcomes will be measured using pooled primary and secondary care clinical and cost-data, as well as clinician questionnaires.

03

Conditions studied

  • Heart Failure
  • Heart Valve Diseases
  • Atrial Fibrillation
  • Heart Murmurs
  • Congestive Heart Failure
  • Heart Failure With Reduced Ejection Fraction

Keywords

  • cluster randomized controlled trial
  • artificial intelligence
  • digital health
  • cardiology
  • primary care
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary care practices that care for adult patients and have the ability to request natriuretic peptide blood testing
  • Primary care practices within the NIHR North West London Clinical Research Network or Betsi Cadwaladr University Health Board.

Exclusion criteria

Exclusion Criteria:

  • Poor WiFi and/or mobile data connectivity within primary care consulting rooms
  • No face-to-face patient consultations
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Intervention

    Receive 3-6 AI-stethoscopes (Eko DUO, Eko Health Inc, CA, USA) including artificial intelligence software for detection of: 1. Reduced left ventricular ejection fraction \<40% 2. Atrial fibrillation 3. Cardiac murmurs

    Device: AI-stethoscope

  • No intervention
    Control

    Usual care

Interventions

  • DeviceAI-stethoscope

    Clinicians at practices in the intervention arm will be provided with one session of in-person training in use of the AI-stethoscope within 2 weeks of randomisation, including 1. Delivery and setup 2. Smartphone app installation and login 3. Pairing of all clinician smartphones with all AI-stethoscopes in the same practice 4. Demo of patient examination The AI-stethoscope will be used within its CE/UKCA-marked intended purpose. The clinical guidelines for use have been agreed by the NHS North West London Integrated Care System and Betsi Cadwaladr University Health Board Cardiovascular Executive Groups. Patients will be examined with the AI-stethoscope in accordance with these guidelines, and/or where stethoscope examination is deemed clinically appropriate. Patients will provide verbal consent for examination with the AI-stethoscope as per any physical examination performed by healthcare professionals for direct care, in accordance with UK law and General Medical Council guidelines.

    Also known as: Eko DUO, Eko Core 500, Eko EAS

06

What researchers measure

Primary outcomes

  1. Incidence of heart failure (co-primary)

    Difference in incidence of coded new diagnoses of heart failure (HF)

    Time frame: 24 months

  2. Ratio of route to diagnosis of heart failure (co-primary) between emergency and community-based pathways

    Difference in ratio of the incidence of coded diagnoses of HF via hospital admission-based versus community-based pathways.

    Time frame: 24 months

Secondary outcomes

  1. Incidence of atrial fibrillation

    New coded diagnoses of atrial fibrillation (AF)

    Time frame: 24 months

  2. Incidence of valvular heart disease

    New coded diagnoses of valvular heart disease (VHD)

    Time frame: 24 months

  3. Cost-consequence (AF)

    Cost-consequence analysis (form of health economic evaluation) for diagnosis of atrial fibrillation, stratified by route to diagnosis. Presented in pounds sterling.

    Time frame: 24 months

  4. Cost-consequence (HFrEF)

    Cost-consequence analysis (form of health economic evaluation) for diagnosis of HFrEF, stratified by route to diagnosis. Presented in pounds sterling.

    Time frame: 24 months

  5. Cost-consequence (VHD)

    Cost-consequence analysis (form of health economic evaluation) for diagnosis of VHD, stratified by route to diagnosis. Presented in pounds sterling.

    Time frame: 24 months

  6. Health service utilisation

    Health service utilisation for diagnostics e.g. rates of request for echocardiography, electrocardiography, primary care appointments. Collected from NHS organisation business intelligence repositories and UK Trusted Research Environments.

    Time frame: 24 months

  7. Proportion of patients prescribed guideline-directed medical therapy

    Proportion of patients prescribedguideline-directed medical therapy (HF, AF, VHD)

    Time frame: 24 months

  8. Device therapy

    New implantation of cardiac resynchronisation therapy (CRT) and/or implantable cardioverter-defibrillator (ICD)

    Time frame: 24 months

  9. Uptake and utilisation

    Differential rates of uptake and utilisation of AI-stethoscope in primary care

    Time frame: 24 months

  10. Determinants of uptake and utilisation

    Determinants of utilisation of AI-stethoscope in primary care (clinician questionnaires)

    Time frame: 24 months

  11. Patient quality of life

    Healthy Days at Home (patient-level analysis)

    Time frame: 24 months

Other outcomes

  1. Sensitivity analysis

    Patient-level sensitivity analyses will be performed for patients with abnormal Eko DUO predictions for HF, to identify direct associations between AI-stethoscope predictions and specific diagnostic codes for HF, AF and VHD

    Time frame: 24 months

07

Study locations

1 site
  • NHS North West London Integrated Care System
    London, United Kingdom
08

References and documents

Publications

  • Bachtiger P, Petri CF, Scott FE, Ri Park S, Kelshiker MA, Sahemey HK, Dumea B, Alquero R, Padam PS, Hatrick IR, Ali A, Ribeiro M, Cheung WS, Bual N, Rana B, Shun-Shin M, Kramer DB, Fragoyannis A, Keene D, Plymen CM, Peters NS. Point-of-care screening for heart failure with reduced ejection fraction using artificial intelligence during ECG-enabled stethoscope examination in London, UK: a prospective, observational, multicentre study. Lancet Digit Health. 2022 Feb;4(2):e117-e125. doi: 10.1016/S2589-7500(21)00256-9. Epub 2022 Jan 5. PubMed 34998740 ↗
  • Bachtiger P, Kelshiker MA, Petri CF, Gandhi M, Shah M, Kamalati T, Khan SA, Hooper G, Stephens J, Alrumayh A, Barton C, Kramer DB, Plymen CM, Peters NS. Survival and health economic outcomes in heart failure diagnosed at hospital admission versus community settings: a propensity-matched analysis. BMJ Health Care Inform. 2023 Mar;30(1):e100718. doi: 10.1136/bmjhci-2022-100718. PubMed 36921978 ↗
  • Kelshiker MA, Bachtiger P, Mansell J, Kramer DB, Nakhare S, Almonte MT, Alrumayh A, Petri CF, Peters A, Costelloe C, Falaschetti E, Barton C, Al-Lamee R, Majeed A, Plymen CM, Peters NS. Triple cardiovascular disease detection with an artificial intelligence-enabled stethoscope (TRICORDER): design and rationale for a decentralised, real-world cluster-randomised controlled trial and implementation study. BMJ Open. 2025 May 21;15(5):e098030. doi: 10.1136/bmjopen-2024-098030. PubMed 40398956 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Jun 2028, 55 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 55 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Dec 2025 → Jun 2028 and completion Dec 2025 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2023
First posted
Aug 14, 2023
StartActual
Oct 25, 2023
Primary completionEst.
Jun 23, 2028was Dec 2025
CompletionEst.
Jun 23, 2028was Dec 2025
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 23, 2025→Jun 23, 2028
Nov 10, 2026
Study completion
Dec 23, 2025→Jun 23, 2028
Nov 10, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40398956 ↗
Nov 10, 2026
Sponsor
Collaborators added: Imperial College Health Partners (ICHP); collaborators removed: Imperial College Health Partners
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40398956 ↗
    Primary completion Dec 23, 2025→Jun 23, 2028
    Study completion Dec 23, 2025→Jun 23, 2028
    Sponsor Collaborators added: Imperial College Health Partners (ICHP); collaborators removed: Imperial College Health Partners
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05987670
Collaborators
Imperial College Health Partners (ICHP)
Responsible party
Sponsor
First posted
Aug 14, 2023
Start date
Oct 25, 2023
Primary completion
Jun 23, 2028 (estimated)
Completion
Jun 23, 2028 (estimated)
Last update
Nov 10, 2026

Study contacts

Nicholas S Peters, MD
principal investigator · Imperial College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion